NEUP
Neuphoria
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NEUP
Neuphoria Therapeutics Inc.
A clinical stage biopharmaceutical company focused on developing treatment methods for brain diseases
100 Summit Dr, Burlington, Massachusetts 01803
Biopharmaceutical
Neuphoria Therapeutics Inc. (formerly Bionomics Limited) was incorporated under the laws of Australia in 1996 and relocated to Delaware and became a domestic company on December 24, 2024. The Company is a clinical-stage biopharmaceutical company developing novel allosteric ion channel modulators designed to transform the lives of patients with severe CNS disorders who have unmet medical needs. The company is developing oral active small molecule negative allosteric modulator and α7 receptor positive allosteric modulator for the treatment of anxiety and stress-related diseases and cognitive dysfunction, respectively. The company is advancing Ead product candidate BNC 210, an oral, proprietary, selective α7 receptor NAM for the chronic treatment of post-traumatic stress disorder and the acute treatment of social anxiety disorder.
Company Financials
Revenue & Expenses
NEUP has released its 2025 Q3 earnings report, with revenue of 9.35M, reflecting a YoY change of NaN%, and net profit of 7.02M, showing a YoY change of 487.49%. The Sankey diagram below clearly presents NEUP's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
